Evidence map›Paper›PMID 39001265›Full record

ArticleDiagnostics (Basel, Switzerland)2024

Chemokine Receptor-4 Targeted PET/CT Imaging with

Bawinile Hadebe, Lerwine Harry, Lerato Gabela, Siphelele Masikane, Maryam Patel, Sizwe Zwane, Venesen Pillay, Presha Bipath, Nonhlanhla Cebekhulu, Nozipho Nyakale and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Development of an Optimized CXCR4-Targeting Theranostic Pair.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Bawinile HadebeDepartment of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Lerwine HarryDepartment of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Lerato GabelaDepartment of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Siphelele MasikaneDepartment of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Maryam PatelDepartment of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Sizwe ZwaneDepartment of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Venesen PillayDepartment of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Presha BipathInkosi Albert Luthuli Central Hospital, Durban 4001, South Africa.ORCID 0000-0001-5697-1058
Nonhlanhla CebekhuluInkosi Albert Luthuli Central Hospital, Durban 4001, South Africa.
Nozipho NyakaleDepartment of Nuclear Medicine, Sefako Makgatho Health Science University, Pretoria 0208, South Africa.
Prathima RamdassDepartment of Nuclear Medicine, Jawaharlal Nehru Hospital, Rose Belle 51829, Mauritius.
Mpumelelo MsimangInkosi Albert Luthuli Central Hospital, Durban 4001, South Africa.
Colleen AldousDepartment of Genetics, College of Health Sciences, University of KwaZulu Natal, Durban 4001, South Africa.
Mike SathekgeDepartment of Nuclear Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa.ORCID 0000-0002-2806-0625
Mariza VorsterDepartment of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.ORCID 0000-0001-5643-1553

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) is common, and its incidence is increasing, particularly in HIV-infected individuals who present with more aggressive disease. Despite aggressive treatment, the prognosis remains poor because of resistance to chemoradiation therapy. So far, studies report very low [ MATERIALS AND

methodsIn this prospective cross-sectional study, twenty-three (23) patients aged 52.9 ± 10.4 (19.6), 17 males and 6 females with primarily diagnosed (

resultsNinety-one percent (21/23) of tumors were visually detected on [

conclusionsIn conclusion, although [

Indexed as

CXCR4head and neck carcinomaHIVPentixaforPET

Identifiers

PMID39001265
PMCPMC11240717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.